Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

International Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of KIACTA in Preventing Renal Function Decline in Patients With AA Amyloidosis

NCT01215747 is registered in ClinicalTrials.gov with C.T. Development America, Inc. as lead sponsor.

NCT NCT01215747
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01215747 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
International Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of KIACTA in Preventing Renal Function Decline in Patients With AA Amyloidosis
Lead sponsor
C.T. Development America, Inc.
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2010
Completion date
March 31, 2016
Enrollment
261 (actual)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

amyloidosis